ATRC AtriCure Inc.

AtriCure Announces Approval for the cryoICEâ„¢ Platform in Japan

MASON, Ohio--(BUSINESS WIRE)--

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation probe. The approval marks the first time that these products will be available in the Japanese market.

“We are pleased to have this approval in hand, and to be able to bring our cryoablation products to the Japanese market,” said Mike Carrel, President and CEO of AtriCure. “This new approval will augment our offerings in the Japanese market and offer a leading solution to cardiac surgeons and the Japanese patients for the treatment of Afib.”

The company’s distributor in Japan, Century Medical Inc. (CMI), worked closely with AtriCure to secure approval. Product will be immediately available for sale as soon as the reimbursement application is completed, which is expected in the fourth quarter.

“Japanese surgeons have been waiting a long time for this moment. We believe many patients will benefit from this technology and look forward to bringing it to market,” said Takahiko Motani, president and CEO of CMI.

About AtriCure

AtriCure, Inc. is a medical device company that provides innovative solutions designed to decrease the global Afib epidemic. AtriCure’s Isolator® Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip® Left Atrial Appendage Management (LAAM) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. AtriCure believes electrophysiologists and cardiothoracic surgeons are adopting its technologies for the treatment of Afib and reduction of Afib related complications. Afib affects more than 33 million people worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

EN
01/11/2016

Underlying

ATRCAtriCure Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AtriCure Inc.

 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure to Host Analyst & Investor Day on March 26, 2025

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expansion at our Analyst and Investor Day. We also look forward to bringing perspectives from key opinion leaders as well as sharing ...

March 12, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Resu...

MASON, Ohio--(BUSINESS WIRE)-- , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key franchises,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “With the breadth and performance of our busi...

February 12, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Resul...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 financial results. Those interested in listening to the conference call should . Participants are encouraged to register more t...

January 22, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year ...

MASON, Ohio--(BUSINESS WIRE)-- , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025. Preliminary, unaudited revenue for fourth quarter 2024 is expected to be $124.3 million, reflecting growth of approximately 17% as r...

January 13, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conf...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure’s management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at . About AtriCure AtriCure, I...

December 23, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch